{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:14:20Z","timestamp":1741666460255,"version":"3.38.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"DOI":"10.7759\/cureus.80345","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T13:27:01Z","timestamp":1741613221000},"source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Response to Treatment With Anti-calcitonin Gene-Related Peptide (CGRP) Antibodies in Real-World Patients With Episodic Migraine: A Two- and Four-Month Prospective Study"],"prefix":"10.7759","author":[{"given":"Abouch","family":"Krymchantowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Jevoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundo P","family":"Silva-N\u00e9to","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana A","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia Vellutini","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Gabriela","family":"Krymchantowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilton Mariano da Silva","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ervin Michelstaedter","family":"Cotrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina M","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020, 383:1866-76. 10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cline uro.2020.105900","article-title":"Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis","volume":"195","author":"Alasad YW","year":"2020","unstructured":"Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis. Clin Neurol Neurosurg. 2020, 195:105900. 10.1016\/j.cline uro.2020.105900","journal-title":"Clin Neurol Neurosurg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst F","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021, 22:128. 10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jaman eurol.2017.3859","article-title":"Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial","volume":"75","author":"Skljarevski V","year":"2018","unstructured":"Skljarevski V, Oakes TM, Zhang Q, et al.. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018, 75:187-93. 10.1001\/jaman eurol.2017.3859","journal-title":"JAMA Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer VL","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018, 75:1080-8. 10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al.. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018, 319:1999-2008. 10.1001\/jama.2018.4853","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709 038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein SD","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al.. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017, 377:2113-22. 10.1056\/NEJMoa1709 038","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke HC","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018, 91:e2211-21. 10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter U","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, et al.. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018, 392:2280-7. 10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari MD","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, et al.. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019, 394:1030-40. 10.1016\/S0140-6736(19)31946-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners WM","year":"2020","unstructured":"Mulleners WM, Kim BK, Lainez MJ, et al.. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020, 19:814-25. 10.1016\/S1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000689","article-title":"How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective","volume":"32","author":"Torres-Ferrus M","year":"2019","unstructured":"Torres-Ferrus M, Alpuente A, Pozo-Rosich P. How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective. Curr Opin Neurol. 2019, 32:395-404. 10.1097\/WCO.0000000000000689","journal-title":"Curr Opin Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/head.14032","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study","volume":"61","author":"Barbanti P","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, et al.. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021, 61:363-72. 10.1111\/head.14032","journal-title":"Headache"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/head.14194","article-title":"Long-term (48\u00a0weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study","volume":"61","author":"Barbanti P","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, et al.. Long-term (48\u00a0weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021, 61:1351-63. 10.1111\/head.14194","journal-title":"Headache"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti P","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, et al.. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022, 23:138. 10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01213-3","article-title":"Association between response to triptans and response to erenumab: real-life data","volume":"22","author":"Frattale I","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, et al.. Association between response to triptans and response to erenumab: real-life data. J Headache Pain. 2021, 22:1. 10.1186\/s10194-020-01213-3","journal-title":"J Headache Pain"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.895476","article-title":"Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine-a real-life study","volume":"13","author":"Nowaczewska M","year":"2022","unstructured":"Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, Meder G, Janiak-Kiszka J, Ka\u017amierczak W. Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine-a real-life study. Front Neurol. 2022, 13:895476. 10.3389\/fneur.2022.895476","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby PJ","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al.. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377:2123-32. 10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al.. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018, 38:1026-37. 10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper S","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al.. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017, 16:425-34. 10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/head.13929","article-title":"The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response","volume":"60","author":"Broessner G","year":"2020","unstructured":"Broessner G, Reuter U, Bonner JH, et al.. The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response. Headache. 2020, 60:2026-40. 10.1111\/head.13929","journal-title":"Headache"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01433-9","article-title":"Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study","volume":"23","author":"Cullum CK","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, et al.. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain. 2022, 23:61. 10.1186\/s10194-022-01433-9","journal-title":"J Headache Pain"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01753-y","article-title":"CGRP-targeted medication in chronic migraine - systematic review","volume":"25","author":"Oliveira R","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine - systematic review. J Headache Pain. 2024, 25:51. 10.1186\/s10194-024-01753-y","journal-title":"J Headache Pain"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1800811","article-title":"Exploring nontraumatic brain hemorrhage in sudden and unexpected deaths: a novel autopsy-based investigation","volume":"20","author":"Kanani J","year":"2025","unstructured":"Kanani J, Sheikh MI. Exploring nontraumatic brain hemorrhage in sudden and unexpected deaths: a novel autopsy-based investigation. Asian J Neurosurg. 2025, 20:126-31. 10.1055\/s-0044-1800811","journal-title":"Asian J Neurosurg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32162","article-title":"Migraine: disease characterisation, biomarkers, and precision medicine","volume":"397","author":"Ashina M","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, et al.. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021, 397:1496-504. 10.1016\/S0140-6736(20)32162","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000262045.11646.b1","article-title":"Obesity, migraine, and chronic migraine: possible mechanisms of interaction","volume":"68","author":"Bigal ME","year":"2007","unstructured":"Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology. 2007, 68:1851-61. 10.1212\/01.wnl.0000262045.11646.b1","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1358\/dnp.2010.23.2.1475909","article-title":"Calcitonin gene-related peptide: a molecular link between obesity and migraine?","volume":"23","author":"Recober A","year":"2010","unstructured":"Recober A, Goadsby PJ. Calcitonin gene-related peptide: a molecular link between obesity and migraine?. Drug News Perspect. 2010, 23:112-7. 10.1358\/dnp.2010.23.2.1475909","journal-title":"Drug News Perspect"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01552-x","article-title":"Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience","volume":"24","author":"Raffaelli B","year":"2023","unstructured":"Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023, 24:16. 10.1186\/s10194-023-01552-x","journal-title":"J Headache Pain"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis","volume":"209","author":"Soni P","year":"2021","unstructured":"Soni P, Chawla E. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis. Clin Neurol Neurosurg. 2021, 209:106893. 10.1016\/j.clineuro.2021.106893","journal-title":"Clin Neurol Neurosurg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.649143","article-title":"Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis","volume":"12","author":"Wang X","year":"2021","unstructured":"Wang X, Chen Y, Song J, You C. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. Front Pharmacol. 2021, 12:649143. 10.3389\/fphar.2021.649143","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/331827-predictors-of-response-to-treatment-with-anti-calcitonin-gene-related-peptide-cgrp-antibodies-in-real-world-patients-with-episodic-migraine-a-two--and-four-month-prospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T13:27:04Z","timestamp":1741613224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/331827-predictors-of-response-to-treatment-with-anti-calcitonin-gene-related-peptide-cgrp-antibodies-in-real-world-patients-with-episodic-migraine-a-two--and-four-month-prospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.80345","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}